Medicines Co. Stock
Price
Target price
-
-
-
-
-
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Medicines Co. in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
B****
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Medicines Co. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medicines Co. | - | - | - | - | - | - | - |
| Repligen Corp. | 1.880% | -0.636% | 29.132% | -1.614% | -10.682% | -39.024% | -14.792% |
| Opko Health Inc. | -3.140% | 0.938% | 12.948% | -1.885% | -7.055% | -27.610% | -63.547% |
| Amicus Therapeutics Inc. | 0.710% | 0.714% | 3.676% | -22.099% | -22.951% | -35.499% | -46.183% |
Comments
News
Royalty Pharma (RPRX) Q2 Receipts Up 20%
Royalty Pharma Plc (NASDAQ:RPRX), a leader in acquiring royalties on biopharmaceutical products, released second quarter results on August 6, 2025. The most notable news: Royalty Receipts—its
BeOne Medicines (ONC) Q2 EPS Soars 924%
BeOne Medicines (NASDAQ:ONC), a global oncology-focused pharmaceutical company, released results for Q2 2025 on August 6, 2025. The most notable news was a sustained acceleration across revenue
Praxis (PRAX) Q2 Loss Widens 90%
Praxis Precision Medicines (NASDAQ:PRAX) is a clinical-stage biopharmaceutical company specializing in therapies for central nervous system (CNS) disorders. On August 4, 2025, it reported financial